Methods Seventy three aged patients with multivessel coronary artery disease complicated undergoing incomplete revascularisation by PCI were divided into trimetazidine group (n=38) and routine therapy group (n=35). MACE events, angina frequency, angina duration and number of CCS class were follow-up at 12 months after PCI. Results The incidence of MACE after 12 months follow-up showed there were signifi cantly differences between two groups, p<0.05. Angina and CCS class were all signifi cantly reduced in trimetazidine group compared to routine therapy group (p<0.05). LVEF and mean distance of 6-min walk test were signifi cantly increased in trimetazidine group after 12 months than those at baseline (p<0.5). The distance of 6-min walk-test in trimetazidine group was longer than that in routine therapy group (p<0.05). Conclusion Trimetazidine could reduce the frequency of angina pectoris events and myocardial damage during PCL. It also improves left ventricular function during follow-up after PCI. 
